<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study was undertaken to determine if there is an association between increased titers of five different <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPLA) in young patients' sera and the occurrence of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Antibodies to anticardiolipin (aCL), anti-phosphatidylserine (aPS), antiphosphatidylinositol (aPI), anti-<z:chebi fb="0" ids="49183">phosphatidylcholine</z:chebi> (aPC), and anti-phosphatidylethanol <z:chebi fb="39" ids="32952">amine</z:chebi> (aPEA) were measured in 214 patients (102 patients, 102 healthy controls and 10 patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>These antibodies were measured twice (within 4h of <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0011009'>acute</z:hpo> myocardial ischemic <z:hpo ids='HP_0100749'>chest pain</z:hpo> and 3 months after the <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>) by enzyme linked immunosorbent assay (ELISA) </plain></SENT>
<SENT sid="3" pm="."><plain>Elevated titers of four different aPLA were detected in 6.9% of <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> on hospitalization </plain></SENT>
<SENT sid="4" pm="."><plain>Titers of aPLA in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> were elevated in the younger age group &lt; 50 years old (P &lt; 0.001) and in men only (not statistically significant) </plain></SENT>
<SENT sid="5" pm="."><plain>No correlation was found between the presence of aPLA and <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> (smoking, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and hyper-<z:e sem="disease" ids="C1392499" disease_type="Disease or Syndrome" abbrv="">cholesterolemia</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>Three of the seven patients with increased titers of aPLA did not have any other <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The titers of aPLA were within <z:mpath ids='MPATH_458'>normal</z:mpath> range 3 months after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Evidence of significantly elevated titers of different aPLA at the early stage of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> suggests that these autoantibodies are present before the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> and are not secondary to them </plain></SENT>
<SENT sid="9" pm="."><plain>The disappearance of the elevated aPLA 3 months after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> may be due to an absorption effect or possibly a cyclic phenomenon similarly found in other <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>aPLA may be an additional risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>, and should especially be considered in a patient of the younger age group without apparent <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
</text></document>